Ruxolitinib, A JAK1/JAK2 Inhibitor, Significantly Prolongs Survival in Both Primary Mediastinal B-Cell Lymphoma & Hodgkin Lymphoma Xenograft NSG Mouse Model: A Potential Targeted Adjuvant Therapy

Lee S.; Yin C.; Shah T.; Ayello J.; Morris E.; van de Ven C.; Cairo M.

首页> 外文期刊>Pediatric blood & cancer >Ruxolitinib, A JAK1/JAK2 Inhibitor, Significantly Prolongs Survival in Both Primary Mediastinal B-Cell Lymphoma & Hodgkin Lymphoma Xenograft NSG Mouse Model: A Potential Targeted Adjuvant Therapy

【24h】

Ruxolitinib, A JAK1/JAK2 Inhibitor, Significantly Prolongs Survival in Both Primary Mediastinal B-Cell Lymphoma & Hodgkin Lymphoma Xenograft NSG Mouse Model: A Potential Targeted Adjuvant Therapy

机译：Ruxolitinib，JAK1 / JAK2抑制剂，在原发性纵隔B细胞淋巴瘤和霍奇金淋巴瘤异种移植NSG小鼠模型中均显着延长生存期：潜在的靶向辅助治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pediatric blood & cancer》 |2016年第3期|共1页
作者
Lee S.; Yin C.; Shah T.; Ayello J.; Morris E.; van de Ven C.; Cairo M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类儿科学;
关键词

相似文献

外文文献
中文文献
专利

1. Ruxolitinib, A JAK1/JAK2 Inhibitor, Significantly Prolongs Survival in Both Primary Mediastinal B-Cell Lymphoma & Hodgkin Lymphoma Xenograft NSG Mouse Model: A Potential Targeted Adjuvant Therapy [J] . Lee S., Yin C., Shah T., Pediatric blood & cancer . 2016,第Suppla3期

机译：Ruxolitinib，JAK1 / JAK2抑制剂，在原发性纵隔B细胞淋巴瘤和霍奇金淋巴瘤异种移植NSG小鼠模型中均显着延长生存期：潜在的靶向辅助治疗
2. Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma. [J] . Calvo KR, Traverse Glehen A, Pittaluga S, Advances in anatomic pathology . 2004,第5期

机译：分子谱分析提供了原发性纵隔大B细胞淋巴瘤作为与经典霍奇金淋巴瘤相关的独特实体的证据：对纵隔灰色区淋巴瘤作为B细胞淋巴瘤的一种中间形式的意义。
3. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma [J] . Eric Van Den Neste, Marc André, Thomas Gastinne, Haematologica . 2018,第5期

机译：口服JAK1 / JAK2抑制剂ruxolitinib在晚期复发/难治性霍奇金淋巴瘤中的II期研究
4. Small-molecule inhibitors targeting survival pathways in B-cell lymphoma. [D] . Arnold, Alan A. 2008

机译：靶向B细胞淋巴瘤生存途径的小分子抑制剂。
5. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL [O] . Yaya Chu, Aradhana Awasthi, Sanghoon Lee, 2020

机译：ObInutuzumab（Ga101）与Rituximab显着增强了细胞死亡抗体依赖性细胞毒性并改善了异种移植Nod-Scid IL2RGNULL（NSG）小鼠模型中的CD20 +原发性纵隔B细胞淋巴瘤（PMBL）的整体存活率：潜在的靶向剂治疗PMBL.
6. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma [O] . Eric Van Den Neste, Marc André, Thomas Gastinne, 2018

机译：先进复发/难治霍奇金淋巴瘤中口腔JAK1 / JAK2抑制剂Ruxolitinib的II期研究

相关主题

Ruxolitinib, A JAK1/JAK2 Inhibitor, Significantly Prolongs Survival in Both Primary Mediastinal B-Cell Lymphoma & Hodgkin Lymphoma Xenograft NSG Mouse Model: A Potential Targeted Adjuvant Therapy

著录项

相似文献

相关主题

期刊订阅